Traditionally imaging of prostate cancer has included ultrasound, CT of abdomen and pelvis, and bone scans. These examinations have a limited detection rate for patients with biochemical recurrence and prostate specific antigen (PSA) below 20 ng/mL. In 2016, guidelines by the European Association of Urology (EAU) and National Comprehensive Cancer Network (NCCN) changed and recommend use of radiolabeled choline PET/CT for selected patients with biochemical recurrence. Our review summarized present knowledge reported in 18 articles with 2213 patients. Read more.